SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Pearl Therapeutics' Phase IIb Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva(R) and Foradil(R) in Patients with COPD